The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
about
Influence of immunoglobulin isotype on therapeutic antibody functionDynamics of macrophage trogocytosis of rituximab-coated B cellsAnalyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesInduced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cRapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.A rheumatoid factor paradox: inhibition of rituximab effector function.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsAntigenic modulation and rituximab resistance.Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.Preferential transfer of certain plasma membrane proteins onto T and B cells by trogocytosis.A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Rituximab: therapeutic benefit! Vitamin R?Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Induction of interleukin-6 production by rituximab in human B cells.Mechanism of Fcγ receptor-mediated trogocytosis-based false-positive results in flow cytometry.HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.Possible implication of Fc γ receptor-mediated trogocytosis in susceptibility to systemic autoimmune diseaseGlycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Rituximab resistance.De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivityAnti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.CD3-positive B cells: a storage-dependent phenomenonRegulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphomaT cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue.Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.Rituximab mediates loss of CD19 on B cells in the absence of cell death.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells.A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cellsMicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation.Rediscovering alemtuzumab: current and emerging therapeutic roles.Anti-CD20 monoclonal antibodies: historical and future perspectives.Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development.
P2860
Q26772080-065C7781-EF8D-472F-BAF6-4621ADCFA1FFQ27314806-FB257FB8-9B0D-401C-8A2B-1F5EC5F55EFFQ27694769-3E5BBC4B-0141-4EB6-B817-7FD190DDE900Q30405847-39BEFA15-EA23-4390-AF27-3650D8562F40Q30408922-672CFCFD-DC2C-4707-9B4F-A374A1BADDE2Q30417730-9D8544DA-358F-47C6-B80D-761B556E2A2CQ30418884-688CDA81-F3A0-4C03-9132-E3E18A47BE88Q30421637-9901603E-F55F-4684-8F82-645574C480F0Q30432874-5CF2ACFE-172C-4DBF-BA39-46EA39573181Q30436996-C736E6A6-9675-4BEB-AD2E-4FEDF8DD4BB3Q30439017-891EE6AC-254E-4AC0-A271-C2EC6D33C1BAQ30453680-F491C004-9973-4078-AF33-C86CAD39B0EBQ33525562-8949E370-9063-4A3A-8111-2D4D1635CD49Q33626106-C2EB5762-B8D3-4FEC-B91D-76E688E6C4F6Q33764056-5FBC9E73-3A62-416C-B99E-6494C9352579Q34223872-4DC4EF8C-0AE9-443E-9522-5AD370734A30Q34310845-4D9ABADE-D057-41EE-8742-19FFE3C70129Q34415869-171A998F-EE43-4A8A-AA7B-4518B44DB743Q34541413-95D89283-7A89-4D87-B005-8A63C9CF0024Q34623592-B3296CD5-AC16-4265-991E-04972C845D04Q34656459-9899A489-B145-4C3B-8990-2BE2BB693087Q34988382-04CC7F91-190D-4ABD-9D0A-2B7B6C6F1BA2Q35041270-5519BFE8-43F3-47B5-9C19-C2FEB1845E86Q35051741-807DFBF5-E381-4E8F-AD0A-D9E25071A7BCQ35170984-60EC72CC-0534-4320-9CB8-C5AF7799B11AQ35346760-0396011D-0F5A-4796-8137-A04EE1A406E8Q35783537-CE4A73BC-8B83-43D1-843D-63419C54C2B8Q35828841-E10327EE-B117-40A5-98CB-F1FCAD422EFFQ36213094-5AA72ED4-3C04-49F9-916F-4918789594CFQ36252683-200E2276-5AB3-4A77-9F9A-17A39E614DB9Q36437030-514DB187-319F-4845-8F45-56A9AB3F89B9Q36713543-47D77AEC-EB9A-43F8-8D6F-BE4118F245E3Q36725445-5E948DC9-E6D5-4694-A365-C0E0D2491A1CQ37022297-24452D63-BADA-4C29-A922-19F706E9C154Q37380881-4ED414E1-0B7A-441C-8492-7034FFD35046Q37381758-2C1B5D52-F4D1-4542-92D9-E35B1825064FQ37601775-3AAD0C0A-3BCE-4497-840F-1EC3D7D8D094Q37676785-007D758B-4722-4B43-BA07-0E0649251995Q37919869-6CCD22FB-23CF-443A-8BA1-8F5B5F647D87Q38051534-28B2BB20-0F5D-40B8-8406-CA79F454AB40
P2860
The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@ast
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@en
type
label
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@ast
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@en
prefLabel
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@ast
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@en
P2093
P1476
The shaving reaction: rituxima ...... emia cells by THP-1 monocytes.
@en
P2093
Adam D Kennedy
Margaret A Lindorfer
Michael E Williams
Paul V Beum
Ronald P Taylor
P304
P356
10.4049/JIMMUNOL.176.4.2600
P407
P577
2006-02-01T00:00:00Z